Jaguar Animal Health (NASDAQ:JAGX) Posts Quarterly Earnings Results, Beats Estimates By $3.90 EPS

Posted by Lindsey Winhoffer on Apr 7th, 2026

Jaguar Animal Health (NASDAQ:JAGX – Get Free Report) released its earnings results on Tuesday. The biotechnology company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($4.26) by $3.90, FiscalAI reports. Jaguar Animal Health had a negative return on equity of 1,194.94% and a negative net margin of 341.90%.The company had revenue of $3.24 million during the quarter, compared to analysts’ expectations of $4.21 million.

Jaguar Animal Health Stock Performance

Shares of JAGX opened at $0.41 on Tuesday. The business’s fifty day moving average price is $0.57 and its 200 day moving average price is $1.18. Jaguar Animal Health has a 12-month low of $0.31 and a 12-month high of $15.48. The stock has a market capitalization of $1.53 million, a PE ratio of -0.01 and a beta of 0.27. The company has a debt-to-equity ratio of 4.08, a current ratio of 0.81 and a quick ratio of 0.52.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. Wall Street Zen cut shares of Jaguar Animal Health to a “strong sell” rating in a research report on Friday, January 23rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jaguar Animal Health in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Jaguar Animal Health has an average rating of “Hold” and a consensus target price of $60.00.

Check Out Our Latest Analysis on Jaguar Animal Health

Jaguar Animal Health Company Profile

(Get Free Report)

Jaguar Animal Health, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments.

Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding.